Key facts
- It has raised $23.4M; the latest was Early Stage VC ($23.4M) in Sep 2025.
- Notable investors include OrbiMed, Biovance Capital Partners, Torrey Pines Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Mondego Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Mondego Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mondego Bio
Developer of targeted molecular therapeutics designed for immune-oncology treatment enhancement. The company is advancing selective inhibitors of PTPN2, a key regulator of the JAK-STAT pathway, with features including modulation of cytokine receptor signaling, improved IFN γ responsiveness, and optimized pharmacological profiles, enabling oncology researchers and clinicians to potentially increase the efficacy of cancer immunotherapy while maintaining favorable safety and tolerability outcomes.
- Sector
- Healthcare
- HQ
- Lisbon, Portugal
- Founded
- 2025
- Website
- mondegobio.com/
- Ownership
- Privately Held (backing)
Mondego Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mondego Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mondego Bio in its N-PORT filings yet. We sweep new filings monthly.